 "Lupin launches anxiety drug duloxetine in US")
Lupin Limited through its subsidiary Lupin Pharmaceuticals Inc, has launched its duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic duloxetine formulation to become available in 40 mg dosage strength. “Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment,” said Lupin in a press release.
Lupin is the only generic manufacturer to offer all duloxetine dosage strengths – the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin’s generic duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength.
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Eli Lilly and marketed under Cymbalta brand, is mostly prescribed for major depressive disorder, generalised anxiety disorder, fibromyalgia and neuropathic pain.
According to IMS MAT June 2015 data, Cymbalta delayed-release capsules 20 mg, 30 mg and 60 mg strengths had annual US sales of approximately $ 1.05 billion.
Lupin is the only generic manufacturer to offer all duloxetine dosage strengths – the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin’s generic duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength.
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) developed by Eli Lilly and marketed under Cymbalta brand, is mostly prescribed for major depressive disorder, generalised anxiety disorder, fibromyalgia and neuropathic pain.
According to IMS MAT June 2015 data, Cymbalta delayed-release capsules 20 mg, 30 mg and 60 mg strengths had annual US sales of approximately $ 1.05 billion.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%